Illustrative image – not actual.
Novavax has entered a supply and license agreement with the Serum Institute of India, Pune, Maharashtra, for development and commercialisation of its COVID-19 vaccine candidate.
The Indian drugmaker will have exclusive rights for the vaccine in India during the term of the deal and non-exclusive rights during the pandemic period in all countries other than those designated by the World Bank as upper-middle or high-income countries.
